BEGIN:VCALENDAR VERSION:2.0 PRODID:-//PsychU - ECPv6.15.16//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:PsychU X-ORIGINAL-URL:https://psychu.org X-WR-CALDESC:Events for PsychU REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:America/New_York BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20240310T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20241103T060000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20250309T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20251102T060000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20260308T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20261101T060000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20270314T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20271107T060000 END:STANDARD END:VTIMEZONE BEGIN:VTIMEZONE TZID:America/Los_Angeles BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20240310T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20241103T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20250309T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20251102T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20260308T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20261101T090000 END:STANDARD END:VTIMEZONE BEGIN:VTIMEZONE TZID:America/Chicago BEGIN:DAYLIGHT TZOFFSETFROM:-0600 TZOFFSETTO:-0500 TZNAME:CDT DTSTART:20240310T080000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0500 TZOFFSETTO:-0600 TZNAME:CST DTSTART:20241103T070000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0600 TZOFFSETTO:-0500 TZNAME:CDT DTSTART:20250309T080000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0500 TZOFFSETTO:-0600 TZNAME:CST DTSTART:20251102T070000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0600 TZOFFSETTO:-0500 TZNAME:CDT DTSTART:20260308T080000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0500 TZOFFSETTO:-0600 TZNAME:CST DTSTART:20261101T070000 END:STANDARD END:VTIMEZONE BEGIN:VTIMEZONE TZID:America/North_Dakota/New_Salem BEGIN:DAYLIGHT TZOFFSETFROM:-0600 TZOFFSETTO:-0500 TZNAME:CDT DTSTART:20240310T080000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0500 TZOFFSETTO:-0600 TZNAME:CST DTSTART:20241103T070000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0600 TZOFFSETTO:-0500 TZNAME:CDT DTSTART:20250309T080000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0500 TZOFFSETTO:-0600 TZNAME:CST DTSTART:20251102T070000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0600 TZOFFSETTO:-0500 TZNAME:CDT DTSTART:20260308T080000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0500 TZOFFSETTO:-0600 TZNAME:CST DTSTART:20261101T070000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=America/New_York:20260408T120000 DTEND;TZID=America/New_York:20260408T130000 DTSTAMP:20260715T062249 CREATED:20260302T202140Z LAST-MODIFIED:20260303T195211Z UID:10004304-1775649600-1775653200@psychu.org SUMMARY:Fact Vs Fiction: Common Misconceptions About Agitation Associated With Alzheimer’s Dementia DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n In this webinar\, presenters will discuss common misconceptions about agitation associated with Alzheimer’s dementia and its treatment. There will be a discussion of evidence-based literature that both challenge and address these misconceptions. Finally\, presenters will share clinical experience in approaching these misconceptions. \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Dina Patel\, MD\, MBA\, DFAPA\n Geriatric Psychiatrist – Founder of Gramercy Psychiatry; Clinical Assistant Professor of Psychiatry in Medicine – Weill Cornell Medical College \n \n \n \n\n\n \n \n \n \n Jehan Marino\, PharmD\, BCPP\n Medical Science Director \n \n \n \n\n\nDr. Patel is a paid consultant of Otsuka Pharmaceutical Development & Commercialization\, Inc. \n\n\n\nDr. Marino is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. \n\n\n\n Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)\, Otsuka America Pharmaceutical\, Inc. (OAPI)\, and Lundbeck\, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as\, nor is it a substitute for\, medical care\, advice\, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC\, OAPI\, and / or Lundbeck\, LLC. \n September 2025    US.CORP.X.25.00194\n \n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n ADHD Neurobiology : The Interplay Between Dopamine\, Norepinephrine\, & Serotonin\n \n Infographic March 25\, 2026\n \n An infographic highlighting the ADHD Neurobiology : The Interplay Between Dopamine\, Norepinephrine\, And Serotonin \n \n \n ADHD Neurobiology: Exploring Dopamine\, Norepinephrine\, & Serotonin in an Integrative Model\n \n On-Demand Webinar March 25\, 2026\n \n In this PsychU webinar\, Stephen V. Faraone\, PhD\, Distinguished Professor of Psychiatry and of Neuroscience and Physiology at SUNY Upstate Medical University\, and examines the evolving understanding of attention-deficit/hyperactivity disorder… \n \n \n The Complexity of ADHD: Symptoms\, Comorbidities & Neurobiology\n \n Video February 25\, 2026\n \n A brief overview of ADHD’s core symptoms\, associated features\, and the roles of dopamine\, norepinephrine\, and serotonin in its clinical presentation. URL:https://psychu.org/event/fact-vs-fiction-common-misconceptions-about-agitation-associated-with-alzheimers-dementia/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/10/Assessment-Tool_Agitation-in-Alzheimers_912x506_shutterstock_716614579.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20260325T120000 DTEND;TZID=America/New_York:20260325T130000 DTSTAMP:20260715T062249 CREATED:20260303T192451Z LAST-MODIFIED:20260321T054634Z UID:10004305-1774440000-1774443600@psychu.org SUMMARY:ADHD Neurobiology: Exploring Dopamine\, Norepinephrine\, and Serotonin in an Integrative Model DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n In this PsychU webinar\, Stephen V. Faraone\, PhD\, Distinguished Professor of Psychiatry and of Neuroscience and Physiology at SUNY Upstate Medical University\, and examines the evolving understanding of attention-deficit/hyperactivity disorder (ADHD) neurobiology. There will be a discussion on how dopamine\, norepinephrine\, and serotonin interact across cortical and subcortical brain regions to influence neural networks\, core ADHD symptoms\, associated features\, and common comorbidities. \n\nJoining Dr. Faraone is Jeffrey Newcorn\, MD\, Medical Director of the Division of ADHD\, Learning Disabilities\, and Related Disorders\, and Director of Pediatric Psychopharmacology at the Mount Sinai Health System. Dr. Newcorn will discuss clinical and translational insights from decades of research in ADHD including neurobiological underpinnings\, physiologic function of monoamine neurotransmitters\, and serotonin system changes in ADHD. \n\nThe session will be moderated by Linzy Hendrickson\, PhD\, Senior Medical Science Liaison\, who will facilitate discussion and Q&A. \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Stephen V Faraone\, PhD\n Distinguished Professor of Psychiatry and of Neuroscience & Physiology\nSUNY Upstate Medical University \n \n \n \n\n\n \n \n \n \n Jeffrey Newcorn\, MD\n Professor of psychiatry and pediatrics\, and director\, Division of ADHD and Learning Disorders at Icahn School of Medicine at Mount Sinai. He is also the director of Pediatric Psychopharmacology for the Mount Sinai Health System\, and supervising psychiatrist in the Student Trainee Mental Health Program at Mount Sinai. \n \n \n \n\n\nModerator\n\n\n\n\n \n \n \n \n Linzy Hendrickson\, PhD\n Senior Medical Science Liaison Texas \n \n \n \n\n\n\nStephen V. Faraone\, PhD\, is Distinguished Professor of Psychiatry and of Neuroscience and Physiology at SUNY Upstate Medical University. A global leader in ADHD research\, he has authored more than 1\,000 scientific publications and is among the most highly cited researchers in psychiatry worldwide. Dr. Faraone has received numerous honors\, including induction into the CHADD Hall of Fame\, the International Society of Psychiatric Genetics Lifetime Achievement Award\, and the Joseph Biederman Lifetime Achievement Award. \n\n\n\nJeffrey Newcorn\, MD\, is Medical Director of the Division of ADHD\, Learning Disabilities\, and Related Disorders and System Director of Pediatric Psychopharmacology at the Mount Sinai Health System. A leading clinician-scientist\, Dr. Newcorn’s work spans clinical\, neurobiological\, and translational research examining ADHD across the lifespan. He has served as principal investigator or co-investigator on multiple NIMH-funded studies exploring ADHD’s clinical presentation\, neurobiological basis\, and treatment response. Dr. Newcorn was a steering committee member for the landmark MTA study and previously served on the DSM-IV advisory committees for child and adolescent disorders. He has authored more than 250 peer-reviewed publications and is nationally recognized for advancing evidence-based ADHD treatment and psychopharmacology. \n\n\n\nLinzy Hendrickson\, PhD\, is a Senior Medical Science Liaison with expertise in behavioral neuroscience\, neuropsychopharmacology\, the neurobiology of addiction\, and substance use disorders. Her experience spans CNS therapeutic areas including epilepsy\, pain\, opioid use disorder\, and schizophrenia. Dr. Hendrickson completed her doctoral training at the University of Massachusetts Medical School and the University of Arizona\, followed by a postdoctoral fellowship at the Waggoner Center for Alcohol & Addiction Research at The University of Texas at Austin. \n\n\n\nDisclaimers\n\n\n\nStephen V. Faraone\, PhD; and Jeffrey Newcorn\, MD  are paid consultants to Otsuka Pharmaceutical Development & Commercialization\, Inc. \n\n\n\nLinzy Hendrickson\, PhD is a paid employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. \n\n\n\n Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)\, Otsuka America Pharmaceutical\, Inc. (OAPI)\, and Lundbeck\, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as\, nor is it a substitute for\, medical care\, advice\, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC\, OAPI\, and / or Lundbeck\, LLC. \n September 2025    US.CORP.X.25.00194\n \n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n ADHD Neurobiology : The Interplay Between Dopamine\, Norepinephrine\, & Serotonin\n \n Infographic March 25\, 2026\n \n An infographic highlighting the ADHD Neurobiology : The Interplay Between Dopamine\, Norepinephrine\, And Serotonin \n \n \n ADHD Neurobiology: Exploring Dopamine\, Norepinephrine\, & Serotonin in an Integrative Model\n \n On-Demand Webinar March 25\, 2026\n \n In this PsychU webinar\, Stephen V. Faraone\, PhD\, Distinguished Professor of Psychiatry and of Neuroscience and Physiology at SUNY Upstate Medical University\, and examines the evolving understanding of attention-deficit/hyperactivity disorder… \n \n \n The Complexity of ADHD: Symptoms\, Comorbidities & Neurobiology\n \n Video February 25\, 2026\n \n A brief overview of ADHD’s core symptoms\, associated features\, and the roles of dopamine\, norepinephrine\, and serotonin in its clinical presentation. URL:https://psychu.org/event/adhd-neurobiology-exploring-dopamine-norepinephrine-and-serotonin-in-an-integrative-model/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/10/Assessment-Tool_Agitation-in-Alzheimers_912x506_shutterstock_716614579.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20251217T120000 DTEND;TZID=America/Los_Angeles:20251217T130000 DTSTAMP:20260715T062249 CREATED:20251104T233342Z LAST-MODIFIED:20251117T174358Z UID:10004289-1765972800-1765976400@psychu.org SUMMARY:Virtual Event - Addressing Unresolved Symptoms of Major Depressive Disorder DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n Objectives:\n\n Understand why many patients with MDD continue to experience unresolved symptoms following first-line treatment\n Understand why the optimal outcome for a patient with MDD involves full symptom recovery\n Discuss different strategies commonly used to address inadequate response to treatment\n Learn how adjunctive atypical antipsychotics (AAPs) fit into the treatment paradigm for patients with MDD\n \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Chet Robachinski\, MD\n Psychiatric Director\, Bailey-Boushay House\, Seattle\, WA; Founding Partner\, Associates in Behavioral Health \n \n \n \n\n\n \n \n \n \n Simon Kim\, PharmD\n Medical Science Liaison \n \n \n \n\n\nChet Robachinski\, MD is a speaker for Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\nSimon Kim\, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Fact Vs Fiction: Common Misconceptions About Agitation Associated With Alzheimer’s Dementia\n \n On-Demand Webinar April 21\, 2026\n \n In this webinar\, presenters will discuss common misconceptions about agitation associated with Alzheimer’s dementia and its treatment. There will be a discussion of evidence-based literature that both challenge and address… \n \n \n Bipolar Disorder By The Numbers\n \n Infographic April 3\, 2026\n \n ~70% of patients with bipolar disorder may be misdiagnosed\, most commonly with depression. Download Infographic \n \n \n A Look At Adherence In Bipolar Disorder\n \n Infographic March 27\, 2026\n \n ~60% of individuals are nonadherent—learn about the outcomes\, key dimensions\, and ways adherence is measured in this downloadable infographic. Download Infographic URL:https://psychu.org/event/virtual-event-addressing-unresolved-symptoms-of-major-depressive-disorder/ CATEGORIES:National,Virtual & Live Events ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2022/08/black-man-using_online-healthcare_digital-health_912x506_shutterstock_1854623368.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20251211T130000 DTEND;TZID=America/New_York:20251211T150000 DTSTAMP:20260715T062249 CREATED:20251024T172021Z LAST-MODIFIED:20251117T171409Z UID:10004284-1765458000-1765465200@psychu.org SUMMARY:Virtual Event - Strategies to Optimize Patient Outcomes in Bipolar I Disorder DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n In this presentation\, the objectives are to:\n\n Understand the impact of mood episode recurrence in bipolar I disorder on patient functioning and clinical outcomes\n Discuss risk factors for mood episode recurrence\, including nonadherence\, in patients with bipolar I disorder\n Review management strategies\, including long-acting injectable antipsychotics (LAIs)\, to optimize patient outcomes in bipolar I disorder\n \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Samantha Canto\, PharmD\n \n \n \n \n\n\n \n \n \n \n Dante Durand\, MD\, MBA\n Vice Chair of Clinical Services & Associate Professor\, Department of Psychiatry and Behavioral Sciences\, University of Miami Miller School of Medicine; Chief Medical Officer at Jackson Behavioral Health Hospital in Miami\, FL. \n \n \n More\n \n Dr. Dante Durand is an Associate Professor and the Vice-Chair of Clinical Services for the Department of Psychiatry at the University of Miami Miller School of Medicine. He is also the Chief Medical Officer at Jackson Behavioral Health Hospital. Dr. Durand’s area of clinical and research interest is schizophrenia. He has written several scientific articles and is the principal investigator on multiple clinical trials in this area. As faculty member\, Dr. Durand has been involved in the education of future generation of psychiatrists and due to his teaching abilities\, he has received multiple honors such as the University of Miami\, Department of Psychiatry Senior Teaching Award for 5 consecutive years. Dr. Durand is a fellow of the American Psychiatric Association\, a member of the American College of Psychiatrists and a board examiner of the American Board of Psychiatry and Neurology.\n \n \n\n\nSamantha Canto\, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\nDante Durand\, MD\, MBA is a speaker for Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Fact Vs Fiction: Common Misconceptions About Agitation Associated With Alzheimer’s Dementia\n \n On-Demand Webinar April 21\, 2026\n \n In this webinar\, presenters will discuss common misconceptions about agitation associated with Alzheimer’s dementia and its treatment. There will be a discussion of evidence-based literature that both challenge and address… \n \n \n Bipolar Disorder By The Numbers\n \n Infographic April 3\, 2026\n \n ~70% of patients with bipolar disorder may be misdiagnosed\, most commonly with depression. Download Infographic \n \n \n A Look At Adherence In Bipolar Disorder\n \n Infographic March 27\, 2026\n \n ~60% of individuals are nonadherent—learn about the outcomes\, key dimensions\, and ways adherence is measured in this downloadable infographic. Download Infographic URL:https://psychu.org/event/virtual-event-strategies-to-optimize-patient-outcomes-in-bipolar-i-disorder-2/ CATEGORIES:National,Virtual & Live Events ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2020/08/Bipolar_head_Mental-Health_200x200_Shutterstock_1211213989-scaled.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20251210T150000 DTEND;TZID=America/New_York:20251210T160000 DTSTAMP:20260715T062249 CREATED:20251008T172519Z LAST-MODIFIED:20251117T165639Z UID:10004277-1765378800-1765382400@psychu.org SUMMARY:Virtual Event - Unmet Needs in Agitation Associated with Dementia Due to Alzheimer’s Disease DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n This evidence-based review highlights important aspects of agitation associated with Alzheimer’s Dementia (AAD) for better understanding of the prevalence and challenges in diagnosis and explore the potential pathobiological correlations in AAD. Describes the clinical and humanistic burden and discusses current guidelines for nonpharmacological and pharmacological treatments of this complex and prominent complication of an already devastating disease. It underlines unmet needs for FDA-approved pharmaceutical treatments for agitation to improve care and quality of life for patients suffering from AAD. \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Becky Wong\, PharmD\, MBA\n Medical Science Director \n \n \n \n\n\n \n \n \n \n David E. Lewis\, DO\n Physician\, Ann’s Choice\, Inc.; Medical Director\, Suncrest Care Hospice; Owner & Provider\, Adult\, Geriatric\, Osteopathic (AGO) Medical Care\, LLC.\n \n \n \n More\n \n Dr David E. Lewis is a Primary Care provider who is Board Certified in both Family Medicine and Geriatric Medicine. He was born and raised in Levittown\, PA and earned his Bachelor of Arts in Biology from Arcadia University and a medical degree from Lake Erie College of Osteopathic Medicine (LECOM). Currently\, Dr Lewis is a primary care physician at Bucks Family Medicine in Pennsylvania\, a part-time medical director at Angelic Healthcare\, and the owner and primary provider at Adult\, Geriatric\, Osteopathic (AGO) Medical Care\, LLC. He is an active member of several professional-medical organizations\, and when Dr. Lewis is not working and making home medical-visits\, he enjoys playing his saxophones.\n \n \n\n\nBecky Wong\, PharmD\, MBA is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\nDavid E. Lewis\, DO is a speaker for Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Fact Vs Fiction: Common Misconceptions About Agitation Associated With Alzheimer’s Dementia\n \n On-Demand Webinar April 21\, 2026\n \n In this webinar\, presenters will discuss common misconceptions about agitation associated with Alzheimer’s dementia and its treatment. There will be a discussion of evidence-based literature that both challenge and address… \n \n \n Bipolar Disorder By The Numbers\n \n Infographic April 3\, 2026\n \n ~70% of patients with bipolar disorder may be misdiagnosed\, most commonly with depression. Download Infographic \n \n \n A Look At Adherence In Bipolar Disorder\n \n Infographic March 27\, 2026\n \n ~60% of individuals are nonadherent—learn about the outcomes\, key dimensions\, and ways adherence is measured in this downloadable infographic. Download Infographic URL:https://psychu.org/event/virtual-event-unmet-needs-in-agitation-associated-with-dementia-due-to-alzheimers-disease/ CATEGORIES:National,Virtual & Live Events ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2022/11/Alzheimer-support_912x506_shutterstock_2128747586.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20251205T120000 DTEND;TZID=America/New_York:20251205T130000 DTSTAMP:20260715T062249 CREATED:20251119T152046Z LAST-MODIFIED:20251119T192859Z UID:10004295-1764936000-1764939600@psychu.org SUMMARY:Virtual Event - Addressing Unresolved Symptoms of Major Depressive Disorder DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n Objectives:\n\n Understand why many patients with MDD continue to experience unresolved symptoms following first-line treatment\n Understand why the optimal outcome for a patient with MDD involves full symptom recovery\n Discuss different strategies commonly used to address inadequate response to treatment\n Learn how adjunctive atypical antipsychotics (AAPs) fit into the treatment paradigm for patients with MDD\n \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Engy Mikhail\, PharmD\n \n \n \n \n\n\n \n \n \n \n Heather Luing\, MD\n Chief Medical Officer\, Florida Center for TMS\nInpatient Psychiatrist\, Flagler Hospital\nPrimary Investigator\, Florida Center for TMS\nConsultant in Forensic Psychiatry \n \n \n More\n \n Dr. Heather Luing is a triple board certified psychiatrist (General\, Forensic and Addiction Medicine) who actively practices in Florida. She completed her medical degree and psychiatric residency and fellowship training at the University of Florida. Her current clinical work includes inpatient psychiatry as the at Flagler Hospital and interventional/outpatient psychiatry as Chief Medical Officer of Florida Center for TMS. Dr. Luing has previously been the Chief Medical Officer of a large Community Mental Health System in Florida. She is currently a Primary Investigator in clinical studies at Florida Center for TMS including the RECOVER trial for Vagus Nerve Stimulation and several pharmaceutical trials. Her special clinical interests include severe mood and thought disorders and specialized treatments for psychiatric illnesses. She also maintains a practice in forensic psychiatry where she serves as a consultant and psychiatric and substance abuse expert for civil cases across the country. She has been an evaluator for impaired licensed professionals\, nurses\, and attorneys in the state of Florida for several years. Dr. Luing also enjoys teaching psychiatric residents in the HCA system.\n \n \n\n\nEngy Mikhail\, PharmD is an employees of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\nHeather Luing\, MD is a speaker for Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Fact Vs Fiction: Common Misconceptions About Agitation Associated With Alzheimer’s Dementia\n \n On-Demand Webinar April 21\, 2026\n \n In this webinar\, presenters will discuss common misconceptions about agitation associated with Alzheimer’s dementia and its treatment. There will be a discussion of evidence-based literature that both challenge and address… \n \n \n Bipolar Disorder By The Numbers\n \n Infographic April 3\, 2026\n \n ~70% of patients with bipolar disorder may be misdiagnosed\, most commonly with depression. Download Infographic \n \n \n A Look At Adherence In Bipolar Disorder\n \n Infographic March 27\, 2026\n \n ~60% of individuals are nonadherent—learn about the outcomes\, key dimensions\, and ways adherence is measured in this downloadable infographic. Download Infographic URL:https://psychu.org/event/virtual-event-addressing-unresolved-symptoms-of-major-depressive-disorder-2/ CATEGORIES:National,Virtual & Live Events ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2021/04/Doctor-holding-patients-hands-e1609855195325.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20251119T120000 DTEND;TZID=America/New_York:20251119T130000 DTSTAMP:20260715T062249 CREATED:20251022T161454Z LAST-MODIFIED:20251117T162109Z UID:10004282-1763553600-1763557200@psychu.org SUMMARY:Psychometric Validation of the AASC®: Supporting Early Detection and Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD) DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n Establishing the psychometric validity of a medical screener tool in the target patient population helps ensure its effectiveness and trustworthiness for clinical use.  Predictive validity of the AASC®\, a brief two-item screener designed to support caregivers and HCPs with early detection of AAD\, has been assessed against the International Psychogeriatric Association (IPA) consensus definition for agitation in cognitive disorders.  In this webinar\, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results. \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Carolyn Clevenger\, DNP\, RN\, GNP-BC\, AGPCNP-BC\, FAANP\, FGSA\n Professor of Transformative Clinical Practice\, Emory University School of Nursing\, Clinical Director and Gerontological Nurse Practitioner at Integrated Memory Care Clinic \n \n \n More\n \n Carolyn Clevenger DNP\, RN\, GNP-BC\, AGPCNP-BC\, FAANP\, FGSA\, is Professor of Transformative Clinical Practice at the Emory University School of Nursing in Atlanta\, Georgia. She serves as Clinical Director and Gerontological Nurse Practitioner at Emory’s Integrated Memory Care Clinic\, a patient-centered medical home providing integrated memory care and primary care for persons living with dementia. She is a Past President of the Gerontological Advanced Practice Nurses Association\, and Fellow of the American Association of Nurse Practitioners (AANP) and the Gerontological Society of America.\n \n \n\n\n \n \n \n \n Jaclyn Beckinghausen\, PhD\n Medical Science Liaison \n \n \n \n\n\nCarolyn Clevenger\, DNP\, RN\, GNP-BC\, AGPCNP-BC\, FAANP\, FGSA is a paid consultant of Otsuka Pharmaceutical Development & Commercialization\, Inc. \n\n\n\nJaclyn Beckinghausen\, PhD is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. \n\n\n\n Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)\, Otsuka America Pharmaceutical\, Inc. (OAPI)\, and Lundbeck\, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as\, nor is it a substitute for\, medical care\, advice\, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC\, OAPI\, and / or Lundbeck\, LLC. \n September 2025    US.CORP.X.25.00194\n \n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n ADHD Neurobiology : The Interplay Between Dopamine\, Norepinephrine\, & Serotonin\n \n Infographic March 25\, 2026\n \n An infographic highlighting the ADHD Neurobiology : The Interplay Between Dopamine\, Norepinephrine\, And Serotonin \n \n \n ADHD Neurobiology: Exploring Dopamine\, Norepinephrine\, & Serotonin in an Integrative Model\n \n On-Demand Webinar March 25\, 2026\n \n In this PsychU webinar\, Stephen V. Faraone\, PhD\, Distinguished Professor of Psychiatry and of Neuroscience and Physiology at SUNY Upstate Medical University\, and examines the evolving understanding of attention-deficit/hyperactivity disorder… \n \n \n The Complexity of ADHD: Symptoms\, Comorbidities & Neurobiology\n \n Video February 25\, 2026\n \n A brief overview of ADHD’s core symptoms\, associated features\, and the roles of dopamine\, norepinephrine\, and serotonin in its clinical presentation. URL:https://psychu.org/event/psychometric-validation-of-the-aasc-supporting-early-detection-and-improving-caregiver-hcp-communication-in-agitation-associated-with-dementia-due-to-alzheimers-disease-aad/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/10/Assessment-Tool_Agitation-in-Alzheimers_912x506_shutterstock_716614579.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Chicago:20251113T160000 DTEND;TZID=America/Chicago:20251115T220000 DTSTAMP:20260715T062249 CREATED:20251029T150454Z LAST-MODIFIED:20251110T201623Z UID:10004288-1763049600-1763244000@psychu.org SUMMARY:The International Conference on ADHD DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n The International Conference on ADHD unites and empowers the ADHD community\, creating a vibrant\, inclusive space where expertise meets lived experience. The conference fosters connections\, sparks insight\, and inspires growth – personally and professionally. Adults with ADHD\, parents and caregivers of children with ADHD\, therapists\, clinicians\, coaches\, educators\, and more all benefit from insightful keynotes\, informative sessions\, interactive workshops\, peer support groups\, and opportunities to network and discover new ADHD tools and strategies. \n\nProduced by CHADD\, ADDA\, and ACO\, the 2025 conference takes place in Kansas City\, MO\, Nov. 13-15\, 2025. \n \n\n\n\nEvent Link\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Fact Vs Fiction: Common Misconceptions About Agitation Associated With Alzheimer’s Dementia\n \n On-Demand Webinar April 21\, 2026\n \n In this webinar\, presenters will discuss common misconceptions about agitation associated with Alzheimer’s dementia and its treatment. There will be a discussion of evidence-based literature that both challenge and address… \n \n \n Bipolar Disorder By The Numbers\n \n Infographic April 3\, 2026\n \n ~70% of patients with bipolar disorder may be misdiagnosed\, most commonly with depression. Download Infographic \n \n \n A Look At Adherence In Bipolar Disorder\n \n Infographic March 27\, 2026\n \n ~60% of individuals are nonadherent—learn about the outcomes\, key dimensions\, and ways adherence is measured in this downloadable infographic. Download Infographic URL:https://psychu.org/event/the-international-conference-on-adhd/ CATEGORIES:Supporter Event ATTACH;FMTTYPE=image/png:https://psychu.org/wp-content/uploads/2021/01/AME-logo.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20251104T120000 DTEND;TZID=America/New_York:20251104T133000 DTSTAMP:20260715T062249 CREATED:20250915T220506Z LAST-MODIFIED:20250915T220517Z UID:10004260-1762257600-1762263000@psychu.org SUMMARY:Virtual Event - Strategies To Optimize Patient Outcomes In Bipolar-I Disorder: Role Of Long-Acting Injectable Antipsychotics DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n In this presentation\, the objectives are to:\n\n Understand the impact of mood episode recurrence in bipolar I disorder on patient functioning and clinical outcomes\n Discuss risk factors for mood episode recurrence\, including nonadherence\, in patients with bipolar I disorder\n Review management strategies\, including long-acting injectable antipsychotics (LAIs)\, to optimize patient outcomes in bipolar I disorder\n \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n David Purselle\, MD\n Board-certified psychiatrist with over 20 years of clinical experience\, Director of Georgia Psychiatric Consultants and an adjunct faculty member at Morehouse School of Medicine \n \n \n More\n \n Dr. David Purselle is a board-certified psychiatrist with over 20 years of clinical experience working in a variety of settings\, including outpatient clinics\, emergency rooms\, and inpatient units at the Atlanta VA Medical Center\, Emory University Hospital\, and Grady Hospital. Currently\, he is the Director of Georgia Psychiatric Consultants and an adjunct faculty member at Morehouse School of Medicine. He is also involved with several clinical research studies studying the effectiveness of various antidepressants\, mood stabilizers\, antipsychotics\, and lithium.\n\nDr. Purselle has been recognized as a physician leader in several forums and presented continuing medical education programs at national and local conferences. He has also served as a consultant for major pharmaceutical corporations providing guidance on development of new therapies for a variety of mental illnesses.\n \n \n\n\n \n \n \n \n Kayci Criss\, PharmD\n \n \n \n \n\n\nDavid Purselle\, MD is a speaker for Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)Kayci Criss\, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Fact Vs Fiction: Common Misconceptions About Agitation Associated With Alzheimer’s Dementia\n \n On-Demand Webinar April 21\, 2026\n \n In this webinar\, presenters will discuss common misconceptions about agitation associated with Alzheimer’s dementia and its treatment. There will be a discussion of evidence-based literature that both challenge and address… \n \n \n Bipolar Disorder By The Numbers\n \n Infographic April 3\, 2026\n \n ~70% of patients with bipolar disorder may be misdiagnosed\, most commonly with depression. Download Infographic \n \n \n A Look At Adherence In Bipolar Disorder\n \n Infographic March 27\, 2026\n \n ~60% of individuals are nonadherent—learn about the outcomes\, key dimensions\, and ways adherence is measured in this downloadable infographic. Download Infographic URL:https://psychu.org/event/virtual-event-strategies-to-optimize-patient-outcomes-in-bipolar-i-disorder-role-of-long-acting-injectable-antipsychotics-3/ CATEGORIES:National,Virtual & Live Events ATTACH;FMTTYPE=image/png:https://psychu.org/wp-content/uploads/2022/05/Bipolar_LAI_912x506_shutterstock_1997810351.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20251015T120000 DTEND;TZID=America/New_York:20251015T130000 DTSTAMP:20260715T062249 CREATED:20250715T182814Z LAST-MODIFIED:20251015T134646Z UID:10004238-1760529600-1760533200@psychu.org SUMMARY:Understanding the Complexity of Attention-Deficit Hyperactivity Disorder DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n Attention Deficit Hyperactivity Disorder (ADHD) is a chronic neurodevelopmental disorder characterized not only by impaired levels of inattention\, hyperactivity\, and/or impulsivity but also several associated features and psychiatric comorbidities1. Dr. Childress will discuss how the interplay between norepinephrine\, dopamine and serotonin plays a critical role in ADHD neurobiology2. Lastly\, Dr. Childress will summarize the unmet needs of current treatments for ADHD and the importance of an integrative approach.\n\nObjectives: \n\n Discuss the heterogeneous experience of individuals living with ADHD\, including associated features and key comorbidities\n Explore the current scientific understanding of ADHD neurobiology\, particularly the roles of dopamine\, norepinephrine\, and serotonin\n Examine the broader impact of ADHD and treatment gaps on functioning and quality of life\n\nReferences:\n\n American Psychiatric Association. 5th ed\, text revision. American Psychiatric Association; 2022.\n Koirala S\, et al. Nat Rev Neurosci. 2024;25(12):759-775.\n \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Ann Childress\, MD\n President of the Center for Psychiatry and Behavioral Medicine\, Inc.\, Las Vegas\, NV \n \n \n \n\n\n \n \n \n \n Jehan Marino\, PharmD\, BCPP\n Medical Science Director \n \n \n \n\n\nAnn Childress\, MD is a paid consultant of Otsuka Pharmaceutical Development & Commercialization\, Inc. \n\n\n\nJehan Marino\, PharmD\, BCPP is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. \n\n\n\n Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)\, Otsuka America Pharmaceutical\, Inc. (OAPI)\, and Lundbeck\, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as\, nor is it a substitute for\, medical care\, advice\, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC\, OAPI\, and / or Lundbeck\, LLC. \n June 2025    US.CORP.X.25.00122\n \n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n ADHD Neurobiology : The Interplay Between Dopamine\, Norepinephrine\, & Serotonin\n \n Infographic March 25\, 2026\n \n An infographic highlighting the ADHD Neurobiology : The Interplay Between Dopamine\, Norepinephrine\, And Serotonin \n \n \n ADHD Neurobiology: Exploring Dopamine\, Norepinephrine\, & Serotonin in an Integrative Model\n \n On-Demand Webinar March 25\, 2026\n \n In this PsychU webinar\, Stephen V. Faraone\, PhD\, Distinguished Professor of Psychiatry and of Neuroscience and Physiology at SUNY Upstate Medical University\, and examines the evolving understanding of attention-deficit/hyperactivity disorder… \n \n \n The Complexity of ADHD: Symptoms\, Comorbidities & Neurobiology\n \n Video February 25\, 2026\n \n A brief overview of ADHD’s core symptoms\, associated features\, and the roles of dopamine\, norepinephrine\, and serotonin in its clinical presentation. URL:https://psychu.org/event/understanding-the-complexity-of-attention-deficit-hyperactivity-disorder/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/png:https://psychu.org/wp-content/uploads/2021/11/ADHD2_912x506_shutterstock_1500978389.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20251014T120000 DTEND;TZID=America/New_York:20251014T140000 DTSTAMP:20260715T062249 CREATED:20250915T215450Z LAST-MODIFIED:20251008T145817Z UID:10004259-1760443200-1760450400@psychu.org SUMMARY:Virtual Event - Management of Major Depressive Disorder: Breaking Through the Barriers DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n In this presentation\, the objectives are to:\n\n To understand that Major Depressive Disorder (MDD) is a serious illness leading to decreased overall patient health and quality of life\n To investigate the effect of inadequate treatment response in MDD on patients and their families\n To recognize predictors of and important considerations for inadequate treatment response in MDD\, including the new DSM-5 specifier for anxious distress\n To consider the importance of proactive treatment decisions\n \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n David Purselle\, MD\n Board-certified psychiatrist with over 20 years of clinical experience\, Director of Georgia Psychiatric Consultants and an adjunct faculty member at Morehouse School of Medicine \n \n \n More\n \n Dr. David Purselle is a board-certified psychiatrist with over 20 years of clinical experience working in a variety of settings\, including outpatient clinics\, emergency rooms\, and inpatient units at the Atlanta VA Medical Center\, Emory University Hospital\, and Grady Hospital. Currently\, he is the Director of Georgia Psychiatric Consultants and an adjunct faculty member at Morehouse School of Medicine. He is also involved with several clinical research studies studying the effectiveness of various antidepressants\, mood stabilizers\, antipsychotics\, and lithium.\n\nDr. Purselle has been recognized as a physician leader in several forums and presented continuing medical education programs at national and local conferences. He has also served as a consultant for major pharmaceutical corporations providing guidance on development of new therapies for a variety of mental illnesses.\n \n \n\n\n \n \n \n \n Kayci Criss\, PharmD\n \n \n \n \n\n\nDavid Purselle\, MD is a speaker for Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\nKayci Criss\, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Fact Vs Fiction: Common Misconceptions About Agitation Associated With Alzheimer’s Dementia\n \n On-Demand Webinar April 21\, 2026\n \n In this webinar\, presenters will discuss common misconceptions about agitation associated with Alzheimer’s dementia and its treatment. There will be a discussion of evidence-based literature that both challenge and address… \n \n \n Bipolar Disorder By The Numbers\n \n Infographic April 3\, 2026\n \n ~70% of patients with bipolar disorder may be misdiagnosed\, most commonly with depression. Download Infographic \n \n \n A Look At Adherence In Bipolar Disorder\n \n Infographic March 27\, 2026\n \n ~60% of individuals are nonadherent—learn about the outcomes\, key dimensions\, and ways adherence is measured in this downloadable infographic. Download Infographic URL:https://psychu.org/event/virtual-event-management-of-major-depressive-disorder-breaking-through-the-barriers/ CATEGORIES:National,Virtual & Live Events ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/08/Depression_group-therapy_912x506_shutterstock_2321772109.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Chicago:20251003T073000 DTEND;TZID=America/Chicago:20251004T150000 DTSTAMP:20260715T062249 CREATED:20250716T205707Z LAST-MODIFIED:20250716T205917Z UID:10004239-1759476600-1759590000@psychu.org SUMMARY:National Network of Depression Centers Best Practices for Mood Disorders in Collaboration with Mayo Clinic 2025 DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n The National Network of Depression Centers (NNDC) Best Practices for Mood Disorders in Collaboration with Mayo Clinic 2025 course aims to provide clinically relevant updates for the management of mood disorders and associated comorbidities across the lifespan. Topics include updates and clinical pearls on treatment-resistant depression and bipolar disorder\, new and novel treatments for depression\, and referral criteria for ketamine\, TMS\, ECT\, and psychedelic therapy. The NNDC faculty are leaders in the field and active clinicians [psychiatrists\, child psychiatrists\, clinical psychologists\, and advanced practice providers (APRN\, CNP\, DNP\, PA-C)]\, informed by new research\, and committed to meet the mission of NNDC – use the power of our network to advance scientific discovery\, and to provide stigma free\, evidence-based care to patients with depressive and bipolar illnesses. \n \n\n\n\nEvent Link\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Fact Vs Fiction: Common Misconceptions About Agitation Associated With Alzheimer’s Dementia\n \n On-Demand Webinar April 21\, 2026\n \n In this webinar\, presenters will discuss common misconceptions about agitation associated with Alzheimer’s dementia and its treatment. There will be a discussion of evidence-based literature that both challenge and address… \n \n \n Bipolar Disorder By The Numbers\n \n Infographic April 3\, 2026\n \n ~70% of patients with bipolar disorder may be misdiagnosed\, most commonly with depression. Download Infographic \n \n \n A Look At Adherence In Bipolar Disorder\n \n Infographic March 27\, 2026\n \n ~60% of individuals are nonadherent—learn about the outcomes\, key dimensions\, and ways adherence is measured in this downloadable infographic. Download Infographic URL:https://psychu.org/event/national-network-of-depression-centers-best-practices-for-mood-disorders-in-collaboration-with-mayo-clinic-2025/ CATEGORIES:Supporter Event ATTACH;FMTTYPE=image/png:https://psychu.org/wp-content/uploads/2025/07/NNDC_logo.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/North_Dakota/New_Salem:20251002T183000 DTEND;TZID=America/North_Dakota/New_Salem:20251002T200000 DTSTAMP:20260715T062249 CREATED:20250828T201236Z LAST-MODIFIED:20250902T161654Z UID:10004253-1759429800-1759435200@psychu.org SUMMARY:Unmet Needs in Agitation Associated with Dementia Due to Alzheimer’s Disease DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n This evidence-based review highlights important aspects of agitation associated with Alzheimer’s Dementia (AAD) for better understanding of the prevalence and challenges in diagnosis and explore the potential pathobiological correlations in AAD. Describes the clinical and humanistic burden and discusses current guidelines for nonpharmacological and pharmacological treatments of this complex and prominent complication of an already devastating disease. It underlines unmet needs for FDA-approved pharmaceutical treatments for agitation to improve care and quality of life for patients suffering from AAD. \n \n\n\n\n\n\n\n \n Venue\n \n \n\n\n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Carolyn McDonald\, PharmD\, BCPS\, BCPP\n Medical Science Liaison\, CNS Field Medical Affairs \n \n \n \n\n\nCarolyn McDonald\, PharmD\, BCPS\, BCPP is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\nPSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS \n PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc.\, Otsuka America Pharmaceutical\, Inc.\, and Lundbeck\, L.L.C.\, committed supporters of the mental health treatment community; as such\, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs. \n PSYCHU MEMBERSHIP ELIGIBILITY \n In accordance with the PhRMA Code on Interactions with Healthcare Professionals\, attendance at PsychU educational programs is limited to appropriate attendees (e.g.\, physician\, clinical professional\, current medical school student\, care manager\, advocate\, recovery coach or an executive and manager of an organization) whose primary role is to provide\, manage\, finance\, study\, or regulate mental health services for adult patients.\n NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements. \n MEMBERSHIP & REGISTRATION \n Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU\, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program\, please visit https://www.PsychU.org/. \n ATTENDANCE LIMITATIONS \n PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs\, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs\, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions\, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com. \n MEAL REPORTING \n The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws. URL:https://psychu.org/event/unmet-needs-in-agitation-associated-with-dementia-due-to-alzheimers-disease/ LOCATION:Harveys\, 424 S Gloster Street Tupelo\, MS 38801\, Tupelo\, MS\, 38801\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2024/10/agitation_library-1.jpeg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20251002T180000 DTEND;TZID=America/New_York:20251002T200000 DTSTAMP:20260715T062249 CREATED:20250905T183901Z LAST-MODIFIED:20250919T154745Z UID:10004256-1759428000-1759435200@psychu.org SUMMARY:Social Determinants of Health DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n In this presentation\, the objectives are to:\n\n Discuss health equity and social determinants of health (SDoH)\n What is the relationship to population health?\n Discuss how SDoH impacts the economics of the population\n Discuss a recent pandemic’s impact and correlation to SDoH\n Discuss how payors utilize SDoH data to influence decisions and program investments\n Discuss how SDoH can impact value-based payment methods\n \n \n\n\n\n\n\n\n \n Venue\n \n \n\n\n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Anna Basoff\, PharmD\n Managed Market Liaison \n \n \n More\n \n \n\nAnna Basoff\, PharmD\, is a Managed Market Liaison for Otsuka covering the US Northeast region. Dr. Basoff gained her Doctor of Pharmacy (PharmD) from Rutgers University. After graduating\, she joined Horizon Blue Cross & Blue Shield of NJ as a clinical pharmacist where she worked on initiatives that included MTM (medication therapy management)\, digital health\, and adherence. In the past\, she has also worked as a pharmacist for Walgreens. She resides in NJ and continues to work with the Rutgers pharmacy students\, as diplomat to their Academy of Managed Care Pharmacy (AMCP) student chapter.\n\n\n \n \n\n\n \n \n \n \n Katie Sulkowski\, PharmD\n Medical Science Liaison \n \n \n \n\n\nAnna Basoff\, PharmD and Katie Sulkowski\, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\nPSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS \n PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc.\, Otsuka America Pharmaceutical\, Inc.\, and Lundbeck\, L.L.C.\, committed supporters of the mental health treatment community; as such\, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs. \n PSYCHU MEMBERSHIP ELIGIBILITY \n In accordance with the PhRMA Code on Interactions with Healthcare Professionals\, attendance at PsychU educational programs is limited to appropriate attendees (e.g.\, physician\, clinical professional\, current medical school student\, care manager\, advocate\, recovery coach or an executive and manager of an organization) whose primary role is to provide\, manage\, finance\, study\, or regulate mental health services for adult patients.\n NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements. \n MEMBERSHIP & REGISTRATION \n Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU\, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program\, please visit https://www.PsychU.org/. \n ATTENDANCE LIMITATIONS \n PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs\, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs\, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions\, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com. \n MEAL REPORTING \n The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws. URL:https://psychu.org/event/social-determinants-of-health-2/ LOCATION:Eleven\, 1150 Smallman Street\, Pittsburgh\, PA\, 15222\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/07/telehealth_912x506_shutterstock_2247296561.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20251001T120000 DTEND;TZID=America/New_York:20251001T130000 DTSTAMP:20260715T062249 CREATED:20250801T145906Z LAST-MODIFIED:20250814T151505Z UID:10004246-1759320000-1759323600@psychu.org SUMMARY:Virtual Event - Pathophysiology of Agitation Associated with Dementia Due to Alzheimer’s Disease - The Potential Role Of The Norepinephrine\, Serotonin & Dopamine (NSD) Neurotransmitter Systems DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n In this presentation\, topics of discussion are:\n\n Loss of behavior regulation in agitation associated with AD\n Monoamine systems in agitation associated with AD pathophysiology\n\n Norepinephrine\n Serotonin\n Dopamine\n\n\n \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Becky Wong\, PharmD\, MBA\n Medical Science Director \n \n \n \n\n\n \n \n \n \n David E. Lewis\, DO\n Physician\, Ann’s Choice\, Inc.; Medical Director\, Suncrest Care Hospice; Owner & Provider\, Adult\, Geriatric\, Osteopathic (AGO) Medical Care\, LLC.\n \n \n \n More\n \n Dr David E. Lewis is a Primary Care provider who is Board Certified in both Family Medicine and Geriatric Medicine. He was born and raised in Levittown\, PA and earned his Bachelor of Arts in Biology from Arcadia University and a medical degree from Lake Erie College of Osteopathic Medicine (LECOM). Currently\, Dr Lewis is a primary care physician at Bucks Family Medicine in Pennsylvania\, a part-time medical director at Angelic Healthcare\, and the owner and primary provider at Adult\, Geriatric\, Osteopathic (AGO) Medical Care\, LLC. He is an active member of several professional-medical organizations\, and when Dr. Lewis is not working and making home medical-visits\, he enjoys playing his saxophones.\n \n \n\n\nBecky Wong\, PharmD\, MBA is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\nDavid E. Lewis\, DO is a paid speaker for Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Fact Vs Fiction: Common Misconceptions About Agitation Associated With Alzheimer’s Dementia\n \n On-Demand Webinar April 21\, 2026\n \n In this webinar\, presenters will discuss common misconceptions about agitation associated with Alzheimer’s dementia and its treatment. There will be a discussion of evidence-based literature that both challenge and address… \n \n \n Bipolar Disorder By The Numbers\n \n Infographic April 3\, 2026\n \n ~70% of patients with bipolar disorder may be misdiagnosed\, most commonly with depression. Download Infographic \n \n \n A Look At Adherence In Bipolar Disorder\n \n Infographic March 27\, 2026\n \n ~60% of individuals are nonadherent—learn about the outcomes\, key dimensions\, and ways adherence is measured in this downloadable infographic. Download Infographic URL:https://psychu.org/event/virtual-event-pathophysiology-of-agitation-associated-with-dementia-due-to-alzheimers-disease-the-potential-role-of-the-norepinephrine-serotonin-dopamine-nsd-neurotransmitter-sys/ CATEGORIES:National,Virtual & Live Events ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/10/Assessment-Tool_Agitation-in-Alzheimers_912x506_shutterstock_716614579.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20250924T120000 DTEND;TZID=America/New_York:20250924T130000 DTSTAMP:20260715T062249 CREATED:20250731T180717Z LAST-MODIFIED:20250731T182015Z UID:10004244-1758715200-1758718800@psychu.org SUMMARY:Mental Health Awareness: Shedding Light on the Interplay between Suicide & Stigma (Part 2) DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n Suicide awareness\, prevention\, and reducing stigma are crucial topics that can save lives and improve mental health outcomes. The impact of suicide is profound and affects not only the individual but also family\, friends\, and the broader community. Our webinar aims to provide updated suicide statistics globally and within the United States\, share the etiology of suicide and assessment tools\, examine the interplay between suicide and stigma in mental health\, and finally discuss protective factors and suicide prevention resources. \n\nNote: This webinar is part 2 of a two-part series. To register for part 1 (before 9/10)\, click here. \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Christine Yu Moutier\, MD\n Esteemed psychiatrist\, Chief Medical Officer of The American Foundation for Suicide Prevention\, and PsychU MDD Section Advisor. \n \n \n More\n \n Christine Yu Moutier is a leader in the field of suicide prevention who joined AFSP in 2013.  It is through her passion and commitment to the work that we see a lasting impact via research\, education and support to communities across the U.S.\n\n\nShe has testified before the U.S. Congress and provided multiple Congressional briefings on suicide prevention\, presented to the White House\, spoken at the National Academy of Sciences\, she co-anchored CNN’s Finding Hope suicide prevention town hall\, and has appeared as an expert in The New York Times\, The Washington Post\, Time magazine\, The Economist\, The Atlantic\, Anderson Cooper 360\, the BBC\, CNN\, NBC and other print and television outlets.\n\n\nThroughout her career she has focused on training healthcare leaders\, physicians\, and patient groups in order to change the healthcare system’s approach to mental health\, fighting stigma and optimizing care for those suffering from mental health conditions. In addition to co-founding AFSP’s San Diego Chapter\, Moutier co-led a successful suicide prevention and depression awareness program for health science faculty\, residents\, and students\, which featured AFSP’s groundbreaking Interactive Screening Program.\n\n\nSince earning her medical degree and training in psychiatry at the University of California\, San Diego\, Moutier has been a practicing psychiatrist\, professor and dean in the UCSD School of Medicine\, medical director of the Inpatient Psychiatric Unit at the VA Medical Center in La Jolla\, and has been clinically active with diverse patient populations\, such as veterans\, Asian refugee populations\, as well as physicians and leaders with mental health conditions. She also served as co-investigator for the Sequenced Treatment Alternatives to Relieve Depression study (STAR*D)\, a large National Institute of Mental Health trial on the treatment of refractory depression.\n\n\nMoutier has authored articles and book chapters for publications such as the Journal of the American Medical Association\, Academic Medicine\, the American Journal of Psychiatry\, the Journal of Clinical Psychiatry\, Psychiatric Times\, Depression and Anxiety\, Academic Psychiatry\, and most recently co-authored Stahl’s Clinical Handbook: Suicide Prevention Edition.\n \n \n\n\n \n \n \n \n Jill Harkavy-Friedman\, PhD\n Senior Vice President of Research\, American Foundation for Suicide Prevention \n \n \n More\n \n Jill Harkavy-Friedman\, Ph.D. is the Senior Vice President of Research at the American Foundation for Suicide Prevention\, where she leads initiatives to fund research\, train investigators\, and share findings to support public awareness and advocacy. With over 40 years of experience as a clinician and researcher\, she has authored more than 130 peer-reviewed publications and is a Fellow of the American Association for the Advancement of Science.\n\nDr. Harkavy-Friedman earned her B.A. in Psychology from the University of Pennsylvania and her Ph.D. in Clinical Psychology from the University of Florida\, completing her internship at Yale-New Haven Hospital. She established the Adolescent Depression and Suicide Program at Montefiore Medical Center and has served as an associate professor at Columbia University. She joined AFSP in 2011 and maintained a clinical practice in Manhattan for nearly four decades.\n \n \n\n\n \n \n \n \n Jehan Marino\, PharmD\, BCPP\n Medical Science Director \n \n \n \n\n\n \n \n \n \n Becky Wong\, PharmD\, MBA\n Medical Science Director \n \n \n \n\n\nChristine Moutier\, MD & Jill Harkavy-Friedman\, Ph.D. are paid consultants of Otsuka Pharmaceutical Development & Commercialization\, Inc. \n\n\n\nJehan Marino\, PharmD\, BCPP & Becky Wong\, PharmD\, MBA are employees of Otsuka Pharmaceutical Development & Commercialization\, Inc. \n\n\n\n Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)\, Otsuka America Pharmaceutical\, Inc. (OAPI)\, and Lundbeck\, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as\, nor is it a substitute for\, medical care\, advice\, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC\, OAPI\, and / or Lundbeck\, LLC. \n June 2025    US.CORP.X.25.00119\n \n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Fact Vs Fiction: Common Misconceptions About Agitation Associated With Alzheimer’s Dementia\n \n On-Demand Webinar April 21\, 2026\n \n In this webinar\, presenters will discuss common misconceptions about agitation associated with Alzheimer’s dementia and its treatment. There will be a discussion of evidence-based literature that both challenge and address… \n \n \n Bipolar Disorder By The Numbers\n \n Infographic April 3\, 2026\n \n ~70% of patients with bipolar disorder may be misdiagnosed\, most commonly with depression. Download Infographic \n \n \n A Look At Adherence In Bipolar Disorder\n \n Infographic March 27\, 2026\n \n ~60% of individuals are nonadherent—learn about the outcomes\, key dimensions\, and ways adherence is measured in this downloadable infographic. Download Infographic URL:https://psychu.org/event/mental-health-awareness-shedding-light-on-the-interplay-between-suicide-stigma-part-2/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/png:https://psychu.org/wp-content/uploads/2018/11/suicide-help_holding-hands_912x506_shutterstock_1324641800.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20250918T183000 DTEND;TZID=America/New_York:20250918T203000 DTSTAMP:20260715T062249 CREATED:20250908T163038Z LAST-MODIFIED:20250908T163045Z UID:10004258-1758220200-1758227400@psychu.org SUMMARY:Live Event - Proposed Role Of Modulating Norepinephrine In Psychiatric Illnesses DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n This live program examines the relationship between norepinephrine and psychiatric illnesses by investigating an overlap between monoaminergic pathways and circuitry\, and demonstrating how malfunctioning cortical circuits can influence emotions\, arousal\, and cognition. \n \n\n\n\n\n\n\n \n Venue\n \n \n\n\n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Erica Cleckler\n \n \n \n \n\n\nErica Cleckler is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\nPSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS \n PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc.\, Otsuka America Pharmaceutical\, Inc.\, and Lundbeck\, L.L.C.\, committed supporters of the mental health treatment community; as such\, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs. \n PSYCHU MEMBERSHIP ELIGIBILITY \n In accordance with the PhRMA Code on Interactions with Healthcare Professionals\, attendance at PsychU educational programs is limited to appropriate attendees (e.g.\, physician\, clinical professional\, current medical school student\, care manager\, advocate\, recovery coach or an executive and manager of an organization) whose primary role is to provide\, manage\, finance\, study\, or regulate mental health services for adult patients.\n NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements. \n MEMBERSHIP & REGISTRATION \n Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU\, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program\, please visit https://www.PsychU.org/. \n ATTENDANCE LIMITATIONS \n PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs\, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs\, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions\, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com. \n MEAL REPORTING \n The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws. URL:https://psychu.org/event/live-event-proposed-role-of-modulating-norepinephrine-in-psychiatric-illnesses/ LOCATION:Bonefish Grill – Augusta\, 2911 Washington Rd\, Augusta\, Georgia\, 30909\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2022/08/shutterstock_1897212106.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20250910T120000 DTEND;TZID=America/New_York:20250910T130000 DTSTAMP:20260715T062249 CREATED:20250613T195133Z LAST-MODIFIED:20250731T181632Z UID:10004229-1757505600-1757509200@psychu.org SUMMARY:Mental Health Awareness: Shedding Light on the Interplay between Suicide & Stigma DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n Suicide awareness\, prevention\, and reducing stigma are crucial topics that can save lives and improve mental health outcomes. The impact of suicide is profound and affects not only the individual but also family\, friends\, and the broader community. Our webinar aims to provide updated suicide statistics globally and within the United States\, share the etiology of suicide and assessment tools\, examine the interplay between suicide and stigma in mental health\, and finally discuss protective factors and suicide prevention resources. \n\nNote: This webinar is part 1 of a two-part series. To register for part 2\, click here. \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Christine Yu Moutier\, MD\n Esteemed psychiatrist\, Chief Medical Officer of The American Foundation for Suicide Prevention\, and PsychU MDD Section Advisor. \n \n \n More\n \n Christine Yu Moutier is a leader in the field of suicide prevention who joined AFSP in 2013.  It is through her passion and commitment to the work that we see a lasting impact via research\, education and support to communities across the U.S.\n\n\nShe has testified before the U.S. Congress and provided multiple Congressional briefings on suicide prevention\, presented to the White House\, spoken at the National Academy of Sciences\, she co-anchored CNN’s Finding Hope suicide prevention town hall\, and has appeared as an expert in The New York Times\, The Washington Post\, Time magazine\, The Economist\, The Atlantic\, Anderson Cooper 360\, the BBC\, CNN\, NBC and other print and television outlets.\n\n\nThroughout her career she has focused on training healthcare leaders\, physicians\, and patient groups in order to change the healthcare system’s approach to mental health\, fighting stigma and optimizing care for those suffering from mental health conditions. In addition to co-founding AFSP’s San Diego Chapter\, Moutier co-led a successful suicide prevention and depression awareness program for health science faculty\, residents\, and students\, which featured AFSP’s groundbreaking Interactive Screening Program.\n\n\nSince earning her medical degree and training in psychiatry at the University of California\, San Diego\, Moutier has been a practicing psychiatrist\, professor and dean in the UCSD School of Medicine\, medical director of the Inpatient Psychiatric Unit at the VA Medical Center in La Jolla\, and has been clinically active with diverse patient populations\, such as veterans\, Asian refugee populations\, as well as physicians and leaders with mental health conditions. She also served as co-investigator for the Sequenced Treatment Alternatives to Relieve Depression study (STAR*D)\, a large National Institute of Mental Health trial on the treatment of refractory depression.\n\n\nMoutier has authored articles and book chapters for publications such as the Journal of the American Medical Association\, Academic Medicine\, the American Journal of Psychiatry\, the Journal of Clinical Psychiatry\, Psychiatric Times\, Depression and Anxiety\, Academic Psychiatry\, and most recently co-authored Stahl’s Clinical Handbook: Suicide Prevention Edition.\n \n \n\n\n \n \n \n \n Jill Harkavy-Friedman\, PhD\n Senior Vice President of Research\, American Foundation for Suicide Prevention \n \n \n More\n \n Jill Harkavy-Friedman\, Ph.D. is the Senior Vice President of Research at the American Foundation for Suicide Prevention\, where she leads initiatives to fund research\, train investigators\, and share findings to support public awareness and advocacy. With over 40 years of experience as a clinician and researcher\, she has authored more than 130 peer-reviewed publications and is a Fellow of the American Association for the Advancement of Science.\n\nDr. Harkavy-Friedman earned her B.A. in Psychology from the University of Pennsylvania and her Ph.D. in Clinical Psychology from the University of Florida\, completing her internship at Yale-New Haven Hospital. She established the Adolescent Depression and Suicide Program at Montefiore Medical Center and has served as an associate professor at Columbia University. She joined AFSP in 2011 and maintained a clinical practice in Manhattan for nearly four decades.\n \n \n\n\n \n \n \n \n Jehan Marino\, PharmD\, BCPP\n Medical Science Director \n \n \n \n\n\n \n \n \n \n Becky Wong\, PharmD\, MBA\n Medical Science Director \n \n \n \n\n\nChristine Moutier\, MD & Jill Harkavy-Friedman\, Ph.D. are paid consultants of Otsuka Pharmaceutical Development & Commercialization\, Inc. \n\n\n\nJehan Marino\, PharmD\, BCPP & Becky Wong\, PharmD\, MBA are employees of Otsuka Pharmaceutical Development & Commercialization\, Inc. \n\n\n\n Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)\, Otsuka America Pharmaceutical\, Inc. (OAPI)\, and Lundbeck\, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as\, nor is it a substitute for\, medical care\, advice\, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC\, OAPI\, and / or Lundbeck\, LLC. \n June 2025    US.CORP.X.25.00119\n \n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Fact Vs Fiction: Common Misconceptions About Agitation Associated With Alzheimer’s Dementia\n \n On-Demand Webinar April 21\, 2026\n \n In this webinar\, presenters will discuss common misconceptions about agitation associated with Alzheimer’s dementia and its treatment. There will be a discussion of evidence-based literature that both challenge and address… \n \n \n Bipolar Disorder By The Numbers\n \n Infographic April 3\, 2026\n \n ~70% of patients with bipolar disorder may be misdiagnosed\, most commonly with depression. Download Infographic \n \n \n A Look At Adherence In Bipolar Disorder\n \n Infographic March 27\, 2026\n \n ~60% of individuals are nonadherent—learn about the outcomes\, key dimensions\, and ways adherence is measured in this downloadable infographic. Download Infographic URL:https://psychu.org/event/mental-health-awareness-shedding-light-on-the-interplay-between-suicide-stigma/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/png:https://psychu.org/wp-content/uploads/2018/11/suicide-help_holding-hands_912x506_shutterstock_1324641800.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Chicago:20250910T073000 DTEND;TZID=America/Chicago:20250911T203000 DTSTAMP:20260715T062250 CREATED:20250716T210419Z LAST-MODIFIED:20250716T211738Z UID:10004240-1757489400-1757622600@psychu.org SUMMARY:2025 NNDC Annual Conference DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n The National Network of Depression Centers (NNDC) is hosting its seventeenth annual conference from September 10-11\, 2025. The conference will feature the signature blend of biological\, psycho-social and systems-level programming that sets the NNDC Annual Conference apart from other major psychiatric CME events. \n\nJoin the NNDC for a dynamic set of discussions\, lectures\, collaboration\, presentations and more! In between rigorous academic courses\, the event will offer plenty of networking opportunities with NNDC members across the nation\, as well as time to connect with this year’s hosts\, the University of Cincinnati\, The Lindner Center of HOPE\, and Cincinnati Children’s Hospital Medical Center. \n\nAs is typical of our conference\, we’re building in lots of breaks to give our members and guests ample face-to-face networking and discussion time. These networking breaks are great opportunities for you as one of our sponsors to renew relationships with world-renowned clinicians\, researchers\, and academic leaders. Breaks will be long enough to give attendees some extra time to connect. \n \n \n\n\n\nEvent Link\n\n\n\nRegistration\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Fact Vs Fiction: Common Misconceptions About Agitation Associated With Alzheimer’s Dementia\n \n On-Demand Webinar April 21\, 2026\n \n In this webinar\, presenters will discuss common misconceptions about agitation associated with Alzheimer’s dementia and its treatment. There will be a discussion of evidence-based literature that both challenge and address… \n \n \n Bipolar Disorder By The Numbers\n \n Infographic April 3\, 2026\n \n ~70% of patients with bipolar disorder may be misdiagnosed\, most commonly with depression. Download Infographic \n \n \n A Look At Adherence In Bipolar Disorder\n \n Infographic March 27\, 2026\n \n ~60% of individuals are nonadherent—learn about the outcomes\, key dimensions\, and ways adherence is measured in this downloadable infographic. Download Infographic URL:https://psychu.org/event/2025-nndc-annual-conference/ CATEGORIES:Supporter Event ATTACH;FMTTYPE=image/png:https://psychu.org/wp-content/uploads/2025/07/NNDC_logo.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20250827T120000 DTEND;TZID=America/New_York:20250827T133000 DTSTAMP:20260715T062250 CREATED:20250711T141754Z LAST-MODIFIED:20250827T165516Z UID:10004235-1756296000-1756301400@psychu.org SUMMARY:Virtual Event - The Impact Of Adherence In Patients With Bipolar I Disorder DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n Treatment non-adherence is a dilemma in bipolar disorder and is one of the leading challenges in providing effective treatments for people diagnosed with BP I disorder. During the discussion\, the speaker discusses and defines some of these challenges and provides the latest information on treatment-related determinants of adherence. We also discuss some of the factors important to adherence. \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Engy Mikhail\, PharmD\n \n \n \n \n\n\n \n \n \n \n Heather Luing\, MD\n Chief Medical Officer\, Florida Center for TMS\nInpatient Psychiatrist\, Flagler Hospital\nPrimary Investigator\, Florida Center for TMS\nConsultant in Forensic Psychiatry \n \n \n More\n \n Dr. Heather Luing is a triple board certified psychiatrist (General\, Forensic and Addiction Medicine) who actively practices in Florida. She completed her medical degree and psychiatric residency and fellowship training at the University of Florida. Her current clinical work includes inpatient psychiatry as the at Flagler Hospital and interventional/outpatient psychiatry as Chief Medical Officer of Florida Center for TMS. Dr. Luing has previously been the Chief Medical Officer of a large Community Mental Health System in Florida. She is currently a Primary Investigator in clinical studies at Florida Center for TMS including the RECOVER trial for Vagus Nerve Stimulation and several pharmaceutical trials. Her special clinical interests include severe mood and thought disorders and specialized treatments for psychiatric illnesses. She also maintains a practice in forensic psychiatry where she serves as a consultant and psychiatric and substance abuse expert for civil cases across the country. She has been an evaluator for impaired licensed professionals\, nurses\, and attorneys in the state of Florida for several years. Dr. Luing also enjoys teaching psychiatric residents in the HCA system.\n \n \n\n\n \n \n \n \n Samantha Canto\, PharmD\n \n \n \n \n\n\nEngy Mikhail\, PharmD and Samantha Canto\, PharmD\, BCPP are employees of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\nHeather Luing\, MD is a speaker for Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Fact Vs Fiction: Common Misconceptions About Agitation Associated With Alzheimer’s Dementia\n \n On-Demand Webinar April 21\, 2026\n \n In this webinar\, presenters will discuss common misconceptions about agitation associated with Alzheimer’s dementia and its treatment. There will be a discussion of evidence-based literature that both challenge and address… \n \n \n Bipolar Disorder By The Numbers\n \n Infographic April 3\, 2026\n \n ~70% of patients with bipolar disorder may be misdiagnosed\, most commonly with depression. Download Infographic \n \n \n A Look At Adherence In Bipolar Disorder\n \n Infographic March 27\, 2026\n \n ~60% of individuals are nonadherent—learn about the outcomes\, key dimensions\, and ways adherence is measured in this downloadable infographic. Download Infographic URL:https://psychu.org/event/virtual-event-the-impact-of-adherence-in-patients-with-bipolar-i-disorder-2/ CATEGORIES:National,Virtual & Live Events ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2021/04/Doctor-with-Checklist_male-patient_shutterstock_200x200_731147215.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20250820T180000 DTEND;TZID=America/Los_Angeles:20250820T190000 DTSTAMP:20260715T062250 CREATED:20250529T005148Z LAST-MODIFIED:20250721T180953Z UID:10004223-1755712800-1755716400@psychu.org SUMMARY:Importance Of Quality in Behavioral Health Care DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n This presentation offers a concise yet impactful exploration of the critical role quality plays in behavioral health care. Key topics include:\n\n The widespread impact of behavioral health disorders on patients\, providers\, payers\, and communities\n An introduction to behavioral health quality measures and their significance\n The rising influence of value-based care models in shaping behavioral health outcomes\n The pivotal role of payers in driving quality improvement\, along with the challenges they face and strategies for achieving success\n\nAttendees will gain valuable insights into how quality-focused approaches can enhance the effectiveness\, efficiency\, and equity of behavioral health care. \n \n\n\n\n\n\n\n \n Venue\n \n \n\n\n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Jodie Malhotra\, PharmD\n CNS Guardian MSL \n \n \n More\n \n Throughout her career\, Jodie has held numerous academic positions at the University of Colorado\, Regis University\, and University of the Incarnate Word.  Jodie also practiced clinically as a Clinical Psychiatric Pharmacist at Denver Health Medical Center.  She completed her Bachelors degree in Chemistry at Lake Forest College\, Doctorate in Pharmacy at Massachusetts College of Pharmacy\, PGY-1 residency at the Cincinnati VA Medical Center\, and her Psychiatric Pharmacy residency at the South Texas Veterans Health Care System.  Jodie is an active member of AAPP and the Colorado Pharmacy Society.  She lives in Denver\, Colorado with her husband\, daughter Maddie\, and dog Indie.\n \n \n\n\n \n \n \n \n Brad Harrison\, RPh\n Managed Market Liaison \n \n \n More\n \n Brad is a licensed pharmacist based in Houston\, Texas who pursued the profession to help others and to improve their quality of life. He is driven by a simple purpose: to improve patient outcomes by ensuring that every decision is guided by solid\, evidence-based insights while focusing on patient access\, outcomes\, and experience.\n\nAs a Managed Market Liaison at Otsuka\, Brad works to connect the dots between medical strategies and the people they serve\, always aiming to bring clarity and value to payers and the patients they serve.\n\nHis journey—from hands-on roles with Clinical teams and Clinical Account Consulting to leading sales strategy—reflects his commitment to understanding how healthcare\, including pharmacy\, functions. With years of practical experience\, Brad chases the everchanging pharmacy landscape and seeks ways to ensure patients get access to the care they need.\n \n \n\n\nJodie Malhotra\, PharmD and Brad Harrison\, RPh are employees of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\nPSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS \n PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc.\, Otsuka America Pharmaceutical\, Inc.\, and Lundbeck\, L.L.C.\, committed supporters of the mental health treatment community; as such\, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs. \n PSYCHU MEMBERSHIP ELIGIBILITY \n In accordance with the PhRMA Code on Interactions with Healthcare Professionals\, attendance at PsychU educational programs is limited to appropriate attendees (e.g.\, physician\, clinical professional\, current medical school student\, care manager\, advocate\, recovery coach or an executive and manager of an organization) whose primary role is to provide\, manage\, finance\, study\, or regulate mental health services for adult patients.\n NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements. \n MEMBERSHIP & REGISTRATION \n Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU\, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program\, please visit https://www.PsychU.org/. \n ATTENDANCE LIMITATIONS \n PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs\, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs\, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions\, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com. \n MEAL REPORTING \n The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws. URL:https://psychu.org/event/importance-of-quality-in-behavioral-health-care-2/ LOCATION:The Gladly\, 2201 E Camleback Rd Unit 106\, Phoenix\, AZ\, 85016\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2021/04/Female-Doctor-Physician-consulting-older-male-patient__Medicare_200x200_shutterstock_1723725679.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20250807T120000 DTEND;TZID=America/Los_Angeles:20250807T130000 DTSTAMP:20260715T062250 CREATED:20250708T085124Z LAST-MODIFIED:20250711T161630Z UID:10004234-1754568000-1754571600@psychu.org SUMMARY:Virtual Event - Pathophysiology Of Agitation Associated With Alzheimer’s Dementia (AD) - The Potential Role Of The Norepinephrine\, Serotonin & Dopamine (NSD) Neurotransmitter Systems DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n https://forms.office.com/Pages/ResponsePage.aspx?id=ObPdNNB_AE-QQcLkf7vJ9KL8Hd6zFFtDh43VOBX0wk5UNTdZSldJSTVNMkg3RlVTSTJMWEZOWVdNRS4u\n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n In this presentation\, topics of discussion are:\n\n Loss of behavior regulation in agitation associated with AD\n Monoamine systems in agitation associated with AD pathophysiology\n\n Norepinephrine\n Serotonin\n Dopamine\n\n\n \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Lea Grinberg Korczyn\, MD\, PhD\n Full Professor & Senior Associate Consultant-Pathology at Mayo Clinic Florida \n \n \n \n\n\n \n \n \n \n Shafa Shah\, PharmD\n Medical Science Liaison \n \n \n \n\n\nLea Grinberg\, MD\, PhD is a speaker for Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\nShafa Shah\, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Fact Vs Fiction: Common Misconceptions About Agitation Associated With Alzheimer’s Dementia\n \n On-Demand Webinar April 21\, 2026\n \n In this webinar\, presenters will discuss common misconceptions about agitation associated with Alzheimer’s dementia and its treatment. There will be a discussion of evidence-based literature that both challenge and address… \n \n \n Bipolar Disorder By The Numbers\n \n Infographic April 3\, 2026\n \n ~70% of patients with bipolar disorder may be misdiagnosed\, most commonly with depression. Download Infographic \n \n \n A Look At Adherence In Bipolar Disorder\n \n Infographic March 27\, 2026\n \n ~60% of individuals are nonadherent—learn about the outcomes\, key dimensions\, and ways adherence is measured in this downloadable infographic. Download Infographic URL:https://psychu.org/event/virtual-event-pathophysiology-of-agitation-associated-with-alzheimers-dementia-ad-the-potential-role-of-the-norepinephrine-serotonin-dopamine-nsd-neurotransmitter-systems-3/ CATEGORIES:National,Virtual & Live Events ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/07/telehealth_912x506_shutterstock_2247296561.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20250730T120000 DTEND;TZID=America/New_York:20250730T130000 DTSTAMP:20260715T062250 CREATED:20250605T170846Z LAST-MODIFIED:20250731T170511Z UID:10004226-1753876800-1753880400@psychu.org SUMMARY:Identifying Challenges and Navigating Treatment Landscape for Management of Agitation Associated with Dementia Due to Alzheimer’s Disease DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n Join us for a discussion with Dr. Douglas McLaughlin\, as he provides perspective on identifying challenges and navigating the treatment landscape for management of agitation associated with dementia due to Alzheimer’s disease.  Both the community and long-term care settings will be explored during this time together. \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Doug McLaughlin\, DO\n Adult Psychiatrist\, Cleveland Clinic \n \n \n More\n \n Dr. Douglas McLaughlin is a board-certified psychiatrist who practices at Cleveland Clinic in Cleveland\, Ohio. Dr. McLaughlin sees patients in both the inpatient and outpatient setting. His expertise is in mood disorders\, anxiety disorders\, ADHD\, schizophrenia and dementia. Dr. McLaughlin is also a Clinical Assistant Professor of Psychiatry at Ohio University College of Osteopathic Medicine.\n \n \n\n\n \n \n \n \n Lindsay Teliska\, PhD\n Medical Science Liaison\, Otsuka Pharmaceutical Development & Commercialization\, Inc. \n \n \n \n\n\n \n \n \n \n Craig Owens\, RPh​\n Long Term Care Medical Science Liaison \n \n \n \n\n\nDouglas McLaughlin\, DO\, is a paid consultant of Otsuka Pharmaceutical Development & Commercialization\, Inc. \n\n\n\nLindsay Teliska\, PhD & Craig Owens\, RPh are employees of Otsuka Pharmaceutical Development & Commercialization\, Inc. \n\n\n\n Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC)\, Otsuka America Pharmaceutical\, Inc. (OAPI)\, and Lundbeck\, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as\, nor is it a substitute for\, medical care\, advice\, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC\, OAPI\, and / or Lundbeck\, LLC. \n June 2025    US.CORP.X.25.00116\n \n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Fact Vs Fiction: Common Misconceptions About Agitation Associated With Alzheimer’s Dementia\n \n On-Demand Webinar April 21\, 2026\n \n In this webinar\, presenters will discuss common misconceptions about agitation associated with Alzheimer’s dementia and its treatment. There will be a discussion of evidence-based literature that both challenge and address… \n \n \n Bipolar Disorder By The Numbers\n \n Infographic April 3\, 2026\n \n ~70% of patients with bipolar disorder may be misdiagnosed\, most commonly with depression. Download Infographic \n \n \n A Look At Adherence In Bipolar Disorder\n \n Infographic March 27\, 2026\n \n ~60% of individuals are nonadherent—learn about the outcomes\, key dimensions\, and ways adherence is measured in this downloadable infographic. Download Infographic URL:https://psychu.org/event/identifying-challenges-and-navigating-treatment-landscape-for-management-of-agitation-associated-with-dementia-due-to-alzheimers-disease/ CATEGORIES:Webinar ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/05/Alzheimers-Dimentia_nurse_patient_912x506_shutterstock_1383653003.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20250724T120000 DTEND;TZID=America/New_York:20250724T130000 DTSTAMP:20260715T062250 CREATED:20250529T174309Z LAST-MODIFIED:20250721T192722Z UID:10004220-1753358400-1753362000@psychu.org SUMMARY:Virtual Event - The Impact Of Adherence In Patients With Bipolar I Disorder DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n Treatment non-adherence is a dilemma in bipolar disorder and is one of the leading challenges in providing effective treatments for people diagnosed with BP I disorder. During the discussion\, the speaker discusses and defines some of these challenges and provides the latest information on treatment-related determinants of adherence. We also discuss some of the factors important to adherence. \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Dante Durand\, MD\, MBA\n Vice Chair of Clinical Services & Associate Professor\, Department of Psychiatry and Behavioral Sciences\, University of Miami Miller School of Medicine; Chief Medical Officer at Jackson Behavioral Health Hospital in Miami\, FL. \n \n \n More\n \n Dr. Dante Durand is an Associate Professor and the Vice-Chair of Clinical Services for the Department of Psychiatry at the University of Miami Miller School of Medicine. He is also the Chief Medical Officer at Jackson Behavioral Health Hospital. Dr. Durand’s area of clinical and research interest is schizophrenia. He has written several scientific articles and is the principal investigator on multiple clinical trials in this area. As faculty member\, Dr. Durand has been involved in the education of future generation of psychiatrists and due to his teaching abilities\, he has received multiple honors such as the University of Miami\, Department of Psychiatry Senior Teaching Award for 5 consecutive years. Dr. Durand is a fellow of the American Psychiatric Association\, a member of the American College of Psychiatrists and a board examiner of the American Board of Psychiatry and Neurology.\n \n \n\n\n \n \n \n \n Samantha Canto\, PharmD\n \n \n \n \n\n\n \n \n \n \n Engy Mikhail\, PharmD\n \n \n \n \n\n\nDante Durand\, MD\, MBA\, Samantha Canto\, PharmD\, BCPP\, and Engy Mikhail\, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Fact Vs Fiction: Common Misconceptions About Agitation Associated With Alzheimer’s Dementia\n \n On-Demand Webinar April 21\, 2026\n \n In this webinar\, presenters will discuss common misconceptions about agitation associated with Alzheimer’s dementia and its treatment. There will be a discussion of evidence-based literature that both challenge and address… \n \n \n Bipolar Disorder By The Numbers\n \n Infographic April 3\, 2026\n \n ~70% of patients with bipolar disorder may be misdiagnosed\, most commonly with depression. Download Infographic \n \n \n A Look At Adherence In Bipolar Disorder\n \n Infographic March 27\, 2026\n \n ~60% of individuals are nonadherent—learn about the outcomes\, key dimensions\, and ways adherence is measured in this downloadable infographic. Download Infographic URL:https://psychu.org/event/virtual-event-the-impact-of-adherence-in-patients-with-bipolar-i-disorder/ CATEGORIES:National,Virtual & Live Events ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2021/04/Primary-Care-Physician_doctor_250x250_shutterstock_1028558461-e1604721074163.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Chicago:20250723T183000 DTEND;TZID=America/Chicago:20250723T203000 DTSTAMP:20260715T062250 CREATED:20250623T171811Z LAST-MODIFIED:20250708T180125Z UID:10004230-1753295400-1753302600@psychu.org SUMMARY:The Impact Of Adherence In Patients With Bipolar I Disorder DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n Treatment non-adherence is a dilemma in bipolar disorder and is one of the leading challenges in providing effective treatments for people diagnosed with BP I disorder. During this discussion\, the speaker discusses and defines some of these challenges and provides the latest information on treatment-related determinants of adherence. We also discuss some of the factors important to adherence. \n \n\n\n\n\n\n\n \n Venue\n \n \n\n\n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Steven Stoner\, PharmD\n Associate Dean for Student Affairs/Clinical Professor\, University of Missouri-Kansas City School of Pharmacy \n \n \n More\n \n Steven Stoner\, PharmD\, BCPP\, is Board Certified in Psychiatric Pharmacy. He is the associate dean of Student Affairs and a Clinical Professor at the UMKC School of Pharmacy. He received his PharmD from the University of Nebraska College of Pharmacy. Dr. Stoner completed a postdoctoral residency in psychiatric pharmacy practice and administration and a fellowship at Western Missouri Mental Health Center in Kansas City\, Missouri.\n \n \n\n\n \n \n \n \n Clayton Levret\, PharmD\n Medical Science Liaison \n \n \n More\n \n Clayton Levret received his PharmD from the University of Kansas. Post-graduation Clayton worked as a clinical pharmacist prior to joining the Otsuka FMA team.\n \n \n\n\nSteven C. Stoner\, PharmD is a speaker for Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC). \n\n\n\nClayton Levret\, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\nPSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS \n PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc.\, Otsuka America Pharmaceutical\, Inc.\, and Lundbeck\, L.L.C.\, committed supporters of the mental health treatment community; as such\, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs. \n PSYCHU MEMBERSHIP ELIGIBILITY \n In accordance with the PhRMA Code on Interactions with Healthcare Professionals\, attendance at PsychU educational programs is limited to appropriate attendees (e.g.\, physician\, clinical professional\, current medical school student\, care manager\, advocate\, recovery coach or an executive and manager of an organization) whose primary role is to provide\, manage\, finance\, study\, or regulate mental health services for adult patients.\n NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements. \n MEMBERSHIP & REGISTRATION \n Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU\, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program\, please visit https://www.PsychU.org/. \n ATTENDANCE LIMITATIONS \n PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs\, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs\, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions\, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com. \n MEAL REPORTING \n The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws. URL:https://psychu.org/event/the-impact-of-adherence-in-patients-with-bipolar-i-disorder-4/ LOCATION:J. Gilbert’s Wood-Fired Steaks & Seafood\, 8901 Metcalf Avenue\, Overland Park\, KS\, 66212\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/png:https://psychu.org/wp-content/uploads/2022/05/Bipolar_LAI_912x506_shutterstock_1997810351.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20250722T183000 DTEND;TZID=America/New_York:20250722T203000 DTSTAMP:20260715T062250 CREATED:20250521T182447Z LAST-MODIFIED:20250522T164719Z UID:10004216-1753209000-1753216200@psychu.org SUMMARY:Collaborative Care In Mental Health DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n In this presentation\, the objectives are to:\n\n Discuss what is collaborative care\n Discuss why is there a need for collaborative care\n Review collaborative care models and outcomes\n Review implementing mental health integrated care\n Discuss challenges to implementing collaborative care programs\n \n \n\n\n\n\n\n\n \n Venue\n \n \n\n\n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Anna Basoff\, PharmD\n Managed Market Liaison \n \n \n More\n \n \n\nAnna Basoff\, PharmD\, is a Managed Market Liaison for Otsuka covering the US Northeast region. Dr. Basoff gained her Doctor of Pharmacy (PharmD) from Rutgers University. After graduating\, she joined Horizon Blue Cross & Blue Shield of NJ as a clinical pharmacist where she worked on initiatives that included MTM (medication therapy management)\, digital health\, and adherence. In the past\, she has also worked as a pharmacist for Walgreens. She resides in NJ and continues to work with the Rutgers pharmacy students\, as diplomat to their Academy of Managed Care Pharmacy (AMCP) student chapter.\n\n\n \n \n\n\n \n \n \n \n Lindsay Teliska\, PhD\n Medical Science Liaison\, Otsuka Pharmaceutical Development & Commercialization\, Inc. \n \n \n \n\n\n \n \n \n \n Yasmin Togun\, PhD\n Medical Science Liaison \n \n \n More\n \n Dr. Yasmin Togun is a CNS Medical Science Liaison at Otsuka\, covering Connecticut\, Massachusetts. Rhode Island\, Vermont\, New Hampshire\, and Maine. She is a Licensed Clinical Psychologist with a focus on Pediatric Psychology and Health Service Psychology. Prior to joining Otsuka\, she practiced as an Attending Psychologist on the Psychiatry Consultation Liaison Service at Boston Children’s Hospital and a Clinical Instructor of Psychology at Harvard Medical School.\n \n \n\n\nAnna Basoff\, PharmD\, Lindsay Teliska\, PhD\, and Yasmin Togun\, PhD are employees of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\nPSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS \n PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc.\, Otsuka America Pharmaceutical\, Inc.\, and Lundbeck\, L.L.C.\, committed supporters of the mental health treatment community; as such\, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs. \n PSYCHU MEMBERSHIP ELIGIBILITY \n In accordance with the PhRMA Code on Interactions with Healthcare Professionals\, attendance at PsychU educational programs is limited to appropriate attendees (e.g.\, physician\, clinical professional\, current medical school student\, care manager\, advocate\, recovery coach or an executive and manager of an organization) whose primary role is to provide\, manage\, finance\, study\, or regulate mental health services for adult patients.\n NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements. \n MEMBERSHIP & REGISTRATION \n Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU\, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program\, please visit https://www.PsychU.org/. \n ATTENDANCE LIMITATIONS \n PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs\, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs\, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions\, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com. \n MEAL REPORTING \n The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws. URL:https://psychu.org/event/collaborative-care-in-mental-health-2/ LOCATION:The Capital Grille\, 410 Legacy Place\, Dedham\, MA\, 02026\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/07/Healthcare_Team_Coordination_912x506_shutterstock_1927967495.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20250626T180000 DTEND;TZID=America/New_York:20250626T203000 DTSTAMP:20260715T062250 CREATED:20250430T143241Z LAST-MODIFIED:20250501T133426Z UID:10004209-1750960800-1750969800@psychu.org SUMMARY:PTSD: Epidemiology\, Trauma Types\, Risk Factors\, Diagnosis\, Clinical Presentation & Course DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n This slide deck will examine the prevalence\, incidence\, and demographics of post-traumatic stress disorder (PTSD)\, explore trauma types\, review important screening and diagnostic tools\, plus delve into the complexities encountered during the initial presentation and subsequent assessment of PTSD. \n \n\n\n\n\n\n\n \n Venue\n \n \n\n\n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Sara A. Spencer\, PharmD\, MS\, BCGP\n Medical Science Liaison \n \n \n \n\n\n \n \n \n \n Yasmin Togun\, PhD\n Medical Science Liaison \n \n \n More\n \n Dr. Yasmin Togun is a CNS Medical Science Liaison at Otsuka\, covering Connecticut\, Massachusetts. Rhode Island\, Vermont\, New Hampshire\, and Maine. She is a Licensed Clinical Psychologist with a focus on Pediatric Psychology and Health Service Psychology. Prior to joining Otsuka\, she practiced as an Attending Psychologist on the Psychiatry Consultation Liaison Service at Boston Children’s Hospital and a Clinical Instructor of Psychology at Harvard Medical School.\n \n \n\n\nSara A. Spencer\, PharmD\, MS\, BCGP and Yasmin Togun\, PhD are employees of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\nPSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS \n PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc.\, Otsuka America Pharmaceutical\, Inc.\, and Lundbeck\, L.L.C.\, committed supporters of the mental health treatment community; as such\, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs. \n PSYCHU MEMBERSHIP ELIGIBILITY \n In accordance with the PhRMA Code on Interactions with Healthcare Professionals\, attendance at PsychU educational programs is limited to appropriate attendees (e.g.\, physician\, clinical professional\, current medical school student\, care manager\, advocate\, recovery coach or an executive and manager of an organization) whose primary role is to provide\, manage\, finance\, study\, or regulate mental health services for adult patients.\n NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements. \n MEMBERSHIP & REGISTRATION \n Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU\, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program\, please visit https://www.PsychU.org/. \n ATTENDANCE LIMITATIONS \n PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs\, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs\, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions\, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com. \n MEAL REPORTING \n The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws. URL:https://psychu.org/event/ptsd-epidemiology-trauma-types-risk-factors-diagnosis-clinical-presentation-course-11/ LOCATION:The Library\, 401 State Street\, Portsmouth\, NH\, 03801\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2021/04/Primary-Care-Physician_doctor_250x250_shutterstock_1028558461-e1604721074163.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/North_Dakota/New_Salem:20250625T120000 DTEND;TZID=America/North_Dakota/New_Salem:20250625T130000 DTSTAMP:20260715T062250 CREATED:20250520T203754Z LAST-MODIFIED:20250605T184900Z UID:10004214-1750852800-1750856400@psychu.org SUMMARY:Virtual Event - Addressing Caregiver Burden and Identifying Agitation in Alzheimer’s Dementia DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n Over 11 million Americans provide unpaid care for people with Alzheimer’s or other dementia.1 The majority (80%) of people with Alzheimer’s disease and related dementia are receiving care in their homes.2 The demand for caregivers and the burden can negatively impact their quality of life and ability to provide care. \n\nThis presentation is intended to highlight the impact of caregiver burden\, which includes a discussion on the challenges in recognizing agitation in Alzheimer’s dementia (AAD) and a review of helpful tools that caregivers can utilize in identifying and managing AAD. \n\nReferences: \n\n Alzheimer’s Association. Facts and figures infographic. https://www.cdc.gov/caregiving/about/?CDC_AAref_Val=https://www.cdc.gov/aging/caregiving/alzheimer.htm. Accessed: September 2024.\n Center for Disease Control and Prevention (CDC). Caregiving for a Person with Alzheimer’s Disease or a Related Dementia. Caregiving for Person with Alzheimer’s Disease or a related Dementia | Alzheimer’s Disease and Healthy Aging | CDC. Accessed: September 2024\n \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Amal Nasher\, PharmD\n \n \n \n \n\n\n \n \n \n \n Lindsey Wright\, PharmD\n Medical Science Liaison \n \n \n \n\n\nAmal Nasher\, PharmD and Lindsey Wright\, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Fact Vs Fiction: Common Misconceptions About Agitation Associated With Alzheimer’s Dementia\n \n On-Demand Webinar April 21\, 2026\n \n In this webinar\, presenters will discuss common misconceptions about agitation associated with Alzheimer’s dementia and its treatment. There will be a discussion of evidence-based literature that both challenge and address… \n \n \n Bipolar Disorder By The Numbers\n \n Infographic April 3\, 2026\n \n ~70% of patients with bipolar disorder may be misdiagnosed\, most commonly with depression. Download Infographic \n \n \n A Look At Adherence In Bipolar Disorder\n \n Infographic March 27\, 2026\n \n ~60% of individuals are nonadherent—learn about the outcomes\, key dimensions\, and ways adherence is measured in this downloadable infographic. Download Infographic URL:https://psychu.org/event/virtual-event-addressing-caregiver-burden-and-identifying-agitation-in-alzheimers-dementia/ CATEGORIES:Regional/Local,Virtual & Live Events ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2021/04/black-doctor_psysician_Electronic-health-record_smart-device_200x200_Shutterstock_157491065.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20250611T120000 DTEND;TZID=America/New_York:20250611T130000 DTSTAMP:20260715T062250 CREATED:20250425T124724Z LAST-MODIFIED:20250527T161254Z UID:10004207-1749643200-1749646800@psychu.org SUMMARY:Virtual Event - Agitation Associated With Alzheimer’s Dementia (AAD) in the Long-Term Care (LTC) Setting - An Introduction to the Agitation in Alzheimer’s Screener for Caregivers (AASCTM) DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n\n\n \n \n \n \n \n \n\n \n \n \n\n \n \n \n \n \n \n\n \n\n\n\n \n \n \n \n \n \n \n \n\n\n\n \n Thank You For Attending Today’s Webinar\n Please tell us what you thought about today’s presentation by taking the survey below: \n \n \n \n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n Objectives\n\n Describe how agitation associated with Alzheimer’s dementia (AAD) can manifest within the long-term care (LTC) setting and the burden that AAD can pose to both residents and caregivers.\n Review current approaches to recognizing and documenting AAD in the LTC setting\, as well as potential challenges faced by nursing home caregivers.\n Discuss the Agitation in Alzheimer’s Screener for Caregivers (AASCTM) and how it may be used to identify and document AAD.\n \n \n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Becky Wong\, PharmD\, MBA\n Medical Science Director \n \n \n \n\n\n \n \n \n \n Carolyn McDonald\, PharmD\, BCPS\, BCPP\n Medical Science Liaison\, CNS Field Medical Affairs \n \n \n \n\n\n \n \n \n \n David E. Lewis\, DO\n Physician\, Ann’s Choice\, Inc.; Medical Director\, Suncrest Care Hospice; Owner & Provider\, Adult\, Geriatric\, Osteopathic (AGO) Medical Care\, LLC.\n \n \n \n More\n \n Dr David E. Lewis is a Primary Care provider who is Board Certified in both Family Medicine and Geriatric Medicine. He was born and raised in Levittown\, PA and earned his Bachelor of Arts in Biology from Arcadia University and a medical degree from Lake Erie College of Osteopathic Medicine (LECOM). Currently\, Dr Lewis is a primary care physician at Bucks Family Medicine in Pennsylvania\, a part-time medical director at Angelic Healthcare\, and the owner and primary provider at Adult\, Geriatric\, Osteopathic (AGO) Medical Care\, LLC. He is an active member of several professional-medical organizations\, and when Dr. Lewis is not working and making home medical-visits\, he enjoys playing his saxophones.\n \n \n\n\nBecky Wong\, PharmD\, MBA and Carolyn McDonald\, PharmD\, BCPS\, BCPP are employees of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\nDavid E. Lewis\, DO is a speaker for Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n \n Related Resources\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Fact Vs Fiction: Common Misconceptions About Agitation Associated With Alzheimer’s Dementia\n \n On-Demand Webinar April 21\, 2026\n \n In this webinar\, presenters will discuss common misconceptions about agitation associated with Alzheimer’s dementia and its treatment. There will be a discussion of evidence-based literature that both challenge and address… \n \n \n Bipolar Disorder By The Numbers\n \n Infographic April 3\, 2026\n \n ~70% of patients with bipolar disorder may be misdiagnosed\, most commonly with depression. Download Infographic \n \n \n A Look At Adherence In Bipolar Disorder\n \n Infographic March 27\, 2026\n \n ~60% of individuals are nonadherent—learn about the outcomes\, key dimensions\, and ways adherence is measured in this downloadable infographic. Download Infographic URL:https://psychu.org/event/virtual-event-agitation-associated-with-alzheimers-dementia-aad-in-the-long-term-care-ltc-setting-an-introduction-to-the-agitation-in-alzheimers-screener-for-caregivers-aasc/ CATEGORIES:National,Virtual & Live Events ATTACH;FMTTYPE=image/jpeg:https://psychu.org/wp-content/uploads/2023/07/Telehealth-call_912x506_shutterstock_2262580799.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20250604T180000 DTEND;TZID=America/New_York:20250604T190000 DTSTAMP:20260715T062250 CREATED:20250418T022135Z LAST-MODIFIED:20250422T135444Z UID:10004198-1749060000-1749063600@psychu.org SUMMARY:Strategies To Optimize Patient Outcomes In Bipolar-I Disorder: Role Of Long-Acting Injectable Antipsychotics DESCRIPTION:Home\n \n \n \n \n Events\n \n \n \n \n \n\n\n\n\n About This Event\n \n \n \n \n \n \n \n \n \n \n Executive Dysfunction & Emotional Dysregulation in ADHD\n In this presentation\, the objectives are to:\n\n Understand the impact of mood episode recurrence in bipolar I disorder on patient functioning and clinical outcomes\n Discuss risk factors for mood episode recurrence\, including nonadherence\, in patients with bipolar I disorder\n Review management strategies\, including long-acting injectable antipsychotics (LAIs)\, to optimize patient outcomes in bipolar I disorder\n \n \n\n\n\n\n\n\n \n Venue\n \n \n\n\n\n\n\n\n\n\n \n Featuring\n \n \n\n\n \n \n \n \n Carl DeFranco\, MSN\, PMHNP-BC\n Psychiatric Mental Health Nurse Practitioner \n \n \n More\n \n Carl DeFranco is a board certified Psychiatric Mental Health Nurse Practitioner through the American Nurses Credentialing Center (ANCC). \nHe has obtained his Professional Registered Nurse degree from Niagara County Community College\, Bachelor of Science in Nursing from Daemen University\, and Master of Science in Nursing from D’Youville University. As a registered nurse he has worked in treatment areas such as hospice\, renal transplant\, Burn Treatment Unit\, and Medical Intensive Care Unit at our local Level 1 Trauma Center in Buffalo\, NY. As a nurse practitioner\, he has worked in outpatient community mental health\, psychiatric homecare\, and Assertive Community Treatment.\n \n \n\n\n \n \n \n \n Sara A. Spencer\, PharmD\, MS\, BCGP\n Medical Science Liaison \n \n \n \n\n\nCarl DeFranco\, MSN\, PMHNP-BC is a paid speaker for Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\nSara A. Spencer\, PharmD\, MS\, BCGP is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n\n\n\n\n\n\n \n Registration\n \n \n \n \n \n \n\n\n\n\n\n\n\n\nPSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS \n PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc.\, Otsuka America Pharmaceutical\, Inc.\, and Lundbeck\, L.L.C.\, committed supporters of the mental health treatment community; as such\, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs. \n PSYCHU MEMBERSHIP ELIGIBILITY \n In accordance with the PhRMA Code on Interactions with Healthcare Professionals\, attendance at PsychU educational programs is limited to appropriate attendees (e.g.\, physician\, clinical professional\, current medical school student\, care manager\, advocate\, recovery coach or an executive and manager of an organization) whose primary role is to provide\, manage\, finance\, study\, or regulate mental health services for adult patients.\n NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements. \n MEMBERSHIP & REGISTRATION \n Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU\, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program\, please visit https://www.PsychU.org/. \n ATTENDANCE LIMITATIONS \n PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs\, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs\, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions\, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com. \n MEAL REPORTING \n The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws. URL:https://psychu.org/event/strategies-to-optimize-patient-outcomes-in-bipolar-i-disorder-role-of-long-acting-injectable-antipsychotics-4/ LOCATION:The Richardson\, 444 Forest Ave\, Buffalo\, NY\, 14213\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/png:https://psychu.org/wp-content/uploads/2022/05/Bipolar_LAI_912x506_shutterstock_1997810351.png END:VEVENT END:VCALENDAR